<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04100174</url>
  </required_header>
  <id_info>
    <org_study_id>18.295</org_study_id>
    <nct_id>NCT04100174</nct_id>
  </id_info>
  <brief_title>Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy</brief_title>
  <acronym>fBTsRT</acronym>
  <official_title>Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if fBT+sRT is superior to standard care in terms of urinary toxicity by having
      fewer patients experience a minimal important decline (MID) in urinary irritation/obstructive
      QoL
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this Phase IIR trial investigators primarily seek to determine if fBT boost (15Gy) to SBRT
      (35Gy/5) can be shown to be superior to standard care (whole-gland BT boost 15Gy to RT
      37.5Gy/15) in terms of urinary toxicity by having fewer patients experience a minimal
      important decline (MID) in urinary irritation/obstructive QoL as measured by ePRO (EPIC-CP)
      at 12 and 24 months post completion of therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Quality of Life</measure>
    <time_frame>12-24 months</time_frame>
    <description>EPIC</description>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>focal brachytherapy boost to SBRT</intervention_name>
    <description>As above</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological diagnosis of prostate cancer planned for curative-intent HDR
             brachytherapy boost to external beam radiotherapy to the prostate gland.

          -  ECOG 0-1

          -  Charlson Comorbidity Index ≤ 4

          -  Imaging visible disease encompassing &lt; 50% of the prostate gland and consistent with
             biopsy findings.

        Exclusion - none
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dianne Trudel</last_name>
    <phone>514-890-8254</phone>
    <email>diane.dt.trudel.chum@ssss.gouv.qc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Trudel</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>26906</phone_ext>
      <email>diane.dt.trudel.chum@ssss.gouv.qc.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2019</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

